Palatin Technologies PTN
NASDAQ PTN
$9.69 -0.76 (-7.23%)
At close: Aug 21, 2026 · 4:00 PM EDT

Palatin Technologies (PTN) Liabilities and Shareholders Equity (2011 - 2026)

Palatin Technologies' (PTN) quarterly Liabilities and Shareholders Equity came in at $13.2 million in Q1 2026, up 254.71% YoY from $3.7 million in Q1 2025, and down 26.23% on a QoQ basis from $17.9 million in Q4 2025.

Palatin Technologies (PTN) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends

Palatin Technologies (PTN) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $13.2 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 254.71% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.0 million (up 93.88% YoY) and the FY2025 annual result came in at $3.3 million, down 69.59% from the prior year.
  • Liabilities and Shareholders Equity fell to $13.2 million in Q1 2026, from $17.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $43.8 million in Q1 2022 to a low of $3.3 million in Q2 2025.
  • A 5-year average of $16.7 million and a median of $13.2 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity plunged 69.64% — and 2025, when it soared 315.95%.
  • Tracing PTN's Liabilities and Shareholders Equity over 5 years: stood at $32.0 million in 2022, then slumped by 57.61% to $13.6 million in 2023, then tumbled by 68.2% to $4.3 million in 2024, then soared by 315.95% to $17.9 million in 2025, then slipped by 26.23% to $13.2 million in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $13.2 million (Q1 2026), $17.9 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 Palatin Technologies 40.37 Mn 40.37 Mn - 13.23 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 13.23 Mn
Dec 31, 2025 17.93 Mn
Sep 30, 2025 8.61 Mn
Jun 30, 2025 3.27 Mn
Mar 31, 2025 3.73 Mn
Dec 31, 2024 4.31 Mn
Sep 30, 2024 3.42 Mn
Jun 30, 2024 10.74 Mn
Mar 31, 2024 11.41 Mn
Dec 31, 2023 13.55 Mn
Sep 30, 2023 11.25 Mn
Jun 30, 2023 17.94 Mn
Mar 31, 2023 25.61 Mn
Dec 31, 2022 31.98 Mn
Sep 30, 2022 27.64 Mn
Jun 30, 2022 36.07 Mn
Mar 31, 2022 43.82 Mn
Dec 31, 2021 52.99 Mn
Sep 30, 2021 59.73 Mn
Jun 30, 2021 67.30 Mn